logo
ResearchBunny Logo
Abstract
This study critically evaluates the Quick Inventory of Depressive Symptomatology, Self-Report, 16 items (QIDS-SR 16) using data from a clinical trial comparing psilocybin therapy (PT) and escitalopram treatment (ET) for major depressive disorder. While 14 of 16 outcome measures favored PT, the QIDS-SR 16 did not. The study investigates reasons for this discrepancy and re-examines between-condition differences at item, facet, and factor levels. Results suggest QIDS-SR 16 limitations, including high variance, imprecise compound items, vague scoring options, and a lack of focus on core depression factors. Re-analysis reveals PT's superiority in reducing depressed mood, anhedonia, and a core depression factor, highlighting potential advantages of PT over ET.
Publisher
Journal of Psychopharmacology
Published On
Jan 01, 2023
Authors
Brandon Weiss, David Erritzoe, Bruna Giribaldi, David J Nutt, Robin L Carhart-Harris
Tags
psilocybin therapy
major depressive disorder
QIDS-SR 16
escitalopram treatment
depression
clinical trial
anhedonia
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs—just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny